UNSPSC 51433405: Falipamil

This classification denotes a calcium channel blocker with the molecular formula C24H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N6A93ZMN7U, chemically known as 2-(3-((3,4-dimethoxyphenetyl)methylamino)propyl)-5,6-dimethoxyphthalimidine but generally known as falipamil, which bears US NIH Compound Identifier 71222. European Medicines Agency schedules Falipamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07500MIG. The term FALIPAMIL is an International Non-Proprietary Name.

UNSPSC 51433405 Falipamil, a Commodity code, covers pharmaceutical products supplied to state and local emergency services, health agencies, and pharmacy benefit programs. State and local governments procure specific medications and pharmaceutical products under this code for emergency medical services, public health programs, and centralized pharmacy distribution networks. The City of Tampa's Tampa Fire Rescue procures advanced life support medications including epinephrine, labetalol, adenosine, and diltiazem through sealed-bid solicitations; the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription programs to streamline pharmaceutical fulfillment; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) establishes statewide and multi-state contracts for generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers. Issuing bodies include municipal fire and emergency services departments, state health and human services agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions. Solicitations typically require vendors to maintain FDA compliance, cGMP certification, and Drug Supply Chain Security Act (DSCSA) adherence, supply products through established pharmaceutical wholesalers, and meet strict expiration-date and shelf-life requirements.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications with a response deadline of April 8, 2026, and an estimated contract value of $40,000.00, featuring a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation. The Texas HHS Commission posted an RFI (No. HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program as a preliminary market intelligence phase. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (No. S1070000015802) due March 26, 2026, to establish multi-year contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026. The Tampa solicitation includes a one-year contract term with two optional one-year renewals plus up to three additional 30-day extensions; the MMCAP RFP establishes two-year terms for new vendors with optional extensions through June 30, 2028.